Mindstate Design Labs

Actual: Feb 1, 2022

$11.5M seed funding

Why it matters: Backed by Y Combinator, Initialized Capital, and founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, and Twitch. Unusually strong Silicon Valley backing for a psychedelic biotech.

Actual: Sep 1, 2024

FDA clearance granted to begin human testing of MSD-001

Why it matters: FDA clearance for 5-MeO-MiPT is notable because the DEA attempted to schedule this compound in January 2022 but withdrew the proposal in July 2022. The regulatory path was uncertain — FDA clearance confirms the compound can proceed clinically.

Actual: Nov 1, 2024

$12.7M Series A raised (total funding ~$24.3M across 3 rounds)

Why it matters: Well-capitalized for continued clinical development. $24M total positions Mindstate for Phase 1 combination trials and potentially Phase 2.

Actual: Sep 24, 2025

Topline Phase 1 results announced: 52 participants (47 evaluable) at CHDR Netherlands. MSD-001 produced strong but narrow psychoactive effects — heightened emotion, associative thinking, enhanced imagination — without hallucinations or ego dissolution. Scored markedly lower on all seven non-visual Altered States of Consciousness scale dimensions vs classical psychedelics. Dose-proportional linear PK. Safe and well-tolerated.

Why it matters: MSD-001 represents a new paradigm: "designed psychedelic experiences" with specific emotional/cognitive effects without the overwhelming perceptual distortion of classical psychedelics. The Osmanthus AI platform (70,000+ trip reports, 600+ effects) predicted this profile. EEG showed engagement of similar neural pathways as classic psychedelics despite the subjectively milder experience — suggesting neuroplasticity without hallucinatory intensity. This could make psychedelic therapy more accessible and scalable.

Actual: Sep 24, 2025

Fixed-dose combination programme announced: MSD-001 + undisclosed compound combining serotonergic + adrenergic targets for anxiolytic effects, enhanced insight, and aesthetic perception ("tranquil insightful beauty")

Why it matters: Moving beyond single-compound psychedelics to rationally designed combinations is unprecedented. The combination targets a specific experiential profile that Osmanthus AI predicted would optimize therapeutic outcomes. Phase 1 of the combination planned.

Watch next: Fixed-dose combination Phase 1 initiation; indication-specific Phase 2 trial design; partnership announcements